Arutimol, eye drops 5 mg/ml 5 ml

Antiglaucoma drug of the group of non-selective beta-adrenoblockers.

Does not have intrinsic sympathomimetic and membrane stabilizing activity. When used topically as eye drops, it reduces both elevated and normal intraocular pressure by reducing the formation of intraocular fluid. It has no effect on accommodation, refraction and pupil size.

The action of the drug is seen 20 minutes after injection into the conjunctival sac. The maximum decrease of intraocular pressure (IOP) is reached within 1-2 hours and lasts for 24 hours.

Pharmacokinetics

Timolol maleate is slightly systemic absorbed when applied topically. After instillation of C _max thymolol in the aqueous humor of the anterior chamber of the eye is reached after 1-2 hours.

In a small amount enters the systemic bloodstream by absorption through the vessels of the conjunctiva, nasal mucous membranes and the lacrimal tract. It is excreted by the kidneys as metabolites.

In infants and young children, C _max timololol in plasma is greater than that in adult plasma.

Indications

Angle-closure glaucoma (in combination with miotics as an additional means to reduce IOP).
Congenital glaucoma (with insufficient effectiveness of other therapeutic measures).
Open angle glaucoma.
Secondary glaucoma (including aphakic).
Increased intraocular pressure (ocular hypertension).

Pharmacological effect

Antiglaucoma drug from the group of non-selective beta-blockers.

It does not have internal sympathomimetic and membrane-stabilizing activity. When applied topically in the form of eye drops, it reduces both elevated and normal intraocular pressure by reducing the formation of intraocular fluid. Does not affect accommodation, refraction or pupil size.

The effect of the drug appears 20 minutes after instillation into the conjunctival sac. The maximum reduction in intraocular pressure (IOP) is achieved after 1-2 hours and persists for 24 hours.

Pharmacokinetics

When applied topically, timolol maleate is slightly subject to systemic absorption. After instillation of eye drops, the Cmax of timolol in the aqueous humor of the anterior chamber of the eye is achieved within 1-2 hours.

In small quantities it enters the systemic circulation by absorption through the vessels of the conjunctiva, mucous membranes of the nose and lacrimal tract. Excreted by the kidneys in the form of metabolites.

In newborns and young children, the Cmax of timolol in the blood plasma exceeds this figure in the blood plasma of adults.

Special instructions

The drug Arutimol is prescribed with caution to patients with impaired liver function, kidney function, or diabetes mellitus.

Within 30 minutes after instillation, you should refrain from engaging in potentially hazardous activities that require increased attention and quick mental and motor reactions.

During treatment, you should not use soft contact lenses, and hard lenses can be worn no earlier than 15 minutes after instillation.

When used together with beta blockers, calcium channel blockers, an excessive decrease in blood pressure may occur.

When using the drug Arutimol, the function of tear secretion, the integrity of the cornea, and the field of vision should be monitored at least once every 6 months.

Active ingredient

Timolol

Composition

Active substance:

Timolol maleate – 6.83 mg (corresponding to timolol 5.0 mg).
Excipients:

Benzalkonium chloride solution (50%) corresponds to benzalkonium chloride,

povidone K 30,

sodium dihydrogen phosphate dihydrate,

sodium monohydrogen phosphate dodecahydrate,

disodium edetate dihydrate,

water for injection.

Pregnancy

Arutimol is contraindicated during pregnancy, breastfeeding and early childhood.

Contraindications

Hypersensitivity to timolol.
Allergic reactions with generalized skin rashes.
Chronic obstructive respiratory diseases (including bronchial asthma).
Severe heart failure.
Sinus bradycardia.
AV block II or III degree.
Cardiogenic shock.
Corneal dystrophy.
Severe atrophic rhinitis.

Use the drug with caution in the following cases:

In patients with thyrotoxicosis.
In patients with chronic bronchitis and emphysema.
In patients with diabetes mellitus receiving insulin or oral hypoglycemic agents (the use of timolol can lead to hypoglycemia).

Side Effects

heart failure
heart rhythm disturbances
shortness of breath, muscle weakness, decreased blood pressure
headache, sleep disturbances, depression
nausea, vomiting, diarrhea
skin allergic reactions
burning in the eyes.

Interaction

Timolol enhances the effect of muscle relaxants.
A decrease in blood pressure and a slowdown in heart rate can be potentiated when Arutimol is used together with calcium channel blockers, reserpine and beta-blockers.
Concomitant use with insulin or oral hypoglycemic agents may lead to hypoglycemia.
Combined use of Arutimol with eye drops containing adrenaline (epinephrine) may cause pupil dilation.
The reduction in IOP is enhanced by the simultaneous use of eye drops containing adrenaline (epinephrine) and pilocarpine.

Overdose

Symptoms: bradycardia, bronchospasm, dizziness, headache, arrhythmia, nausea, vomiting.

Treatment: rinse eyes with water or saline; If necessary, carry out symptomatic therapy.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf life

36 months. After opening the bottle – 6 weeks.

Manufacturer

Dr. Gerhard Mann HFP, Germany